Πλοήγηση ανά Θέμα "Bence Jones protein"

Αποτελέσματα 1-2 από 2

Immunoglobulin D myeloma: Clinical features and outcome in the era of novel agents

Zagouri, F.; Kastritis, E.; Symeonidis, A. S.; Giannakoulas, N.; Katodritou, E.; Delimpasi, S.; Repousis, P.; Terpos, E.; Dimopoulos, M. A. (2014)

Objectives: Immunoglobulin D (IgD) multiple myeloma is an uncommon variant of the disease probably associated with poorer prognosis. However, data on IgD myeloma patients treated in the novel agent era are lacking. Methods: ...
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: A multicenter national study by the Greek Myeloma Study Group

Katodritou E., Terpos E., Delimpasi S., Kotsopoulou M., Michalis E., Vadikolia C., Kyrtsonis M.-C., Symeonidis A., Giannakoulas N., Vadikolia C., Michael M., Kalpadakis C., Gougopoulou T., Prokopiou C., Kaiafa G., Christoulas D., Gavriatopoulou M., Giannopoulou E., Labropoulou V., Verrou E., Kastritis E., Konstantinidou P., Anagnostopoulos A., Dimopoulos M.A. (2018)

We have studied the efficacy and the prognostic impact of novel agents in 50 primary plasma cell leukemia (pPCL) patients registered in our database. Eighty percent of patients were treated upfront with novel agent-based ...